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ABSTRACT  
 
 
 
REBECCA GRIESEMER 
Index Of Central Obesity As A Parameter To Evaluate Metabolic Syndrome For White, 
Black, And Hispanic Adults In The United States 
 
 
Metabolic syndrome is a cluster of disorders including central obesity, hypertension, 
dyslipidemia, and hyperglycemia.  Today’s metabolic syndrome definitions identify central 
obesity by waist circumference (WC) measurements. A recent pilot study suggests that cut-
points derived from a waist-to-height ratio (WHtR), or Index of Central Obesity (ICO), is a 
more accurate measurement of central obesity. This study compared the association between 
the metabolic syndrome components and central obese parameters (ICO and WC) among the 
white, black, and Hispanic adults in the United States.  The subjects’ data was obtained from 
the 2005-2006 National Health and Nutrition Examination Survey.  ICO was highly 
correlated with metabolic syndrome components among white subjects and the least 
correlated in Hispanic subjects.  Multivariate logistic regression analysis did not indicate that 
ICO was a better parameter for metabolic syndrome than WC.  Other WHtR cut-points may 
be more sensitive in predicting metabolic syndrome components than the values used in this 
study. 
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cardiovascular disease 
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CHAPTER I 
INTRODUCTION 
 
The association between certain metabolic disorders and cardiovascular disease 
was first recognized in the 1940’s.1  Professor Jean Vague proposed that upper body 
obesity was better correlated with diabetes and cardiovascular disease than excess body 
weight.2, 3  Vague used the terms “android adiposity” to describe the accumulation of fat 
around the abdomen and “gynoid adiposity” to describe the accumulation of fat found in 
the hips and thigh region.3  Vague studied the differences between the body fat 
topographies and concluded that the obese gynoid phenotype was associated with 
“mechanical complications” and the android phenotype was associated with metabolic 
disturbances.  
During the 1960’s, other researchers observed a relationship between obesity and 
various metabolic related disorders.4  Dr. Reaven, in 1988, first described the cluster of 
metabolic disorders related to insulin resistance.5, 6   Reaven referred to this constellation 
of disorders as “Syndrome X”.  Insulin resistance was the common denominator, 
according to Reaven, and was associated with a hypertriglyceridemia, a decrease in high 
density lipoprotein (HDL), and hypertension.  However, Reaven omitted obesity as a 
component of Syndrome X since he argued that insulin resistance could be found in non-
obese individuals.5  
With the advancement of imaging techniques such as computer tomography (CT), 
researchers were able to accurately distinguish between distributions of fat and showed 
an association between central obesity and metabolic disorders.7, 8  This new
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technology demonstrated how individuals with “normal” weight could have an unhealthy 
accumulation of abdominal fat and develop metabolic risk factors, thus corroborating 
Reaven’s finding of insulin resistance in persons with normal weight, but centrally 
obesity.  Since Reaven’s “Syndrome X”, the constellation of diabetes and cardiovascular 
risk factors has been changed to “metabolic syndrome”, with central obesity as a required 
variable of the syndrome.9-11   
Although the physiopathological mechanism by which central obesity fosters 
metabolic syndrome is debatable, some theories have been widely accepted.12  Visceral 
fat in the truncal region is of particular importance. Compared to subcutaneous fat, 
visceral fat has a higher rate of lipolysis with release of free fatty acids (FFA).12-14  
Elevated levels of FFAs are known to impair insulin function and glucose uptake. FFAs 
mobilized from visceral fat pass directly to the liver via the portal vein, leading to 
hyperglycemia, hepatic insulin resistance, and dyslipidemia, hyperinsulinemia , and 
decreased skeletal muscle insulin sensitivity.13  In contrast, the subcutaneous fat found in 
the femoral-gluteal region plays a less active role in lipolysis and FFA circulation and 
may be a protective factor for metabolic disorders.14  The subcutaneous fat depot acts as a 
“safe haven for the sequestration of excess calories”14 and prevents FFA circulation and 
fat storage in the liver, skeletal muscle and pancreas.15, 16 
Currently, most health professionals agree that five components define the 
metabolic syndrome: obesity, elevated triglycerides, reduced HDL, elevated blood 
glucose, and hypertension.17 18, 19  However, the clinical parameters used to identify 
metabolic syndrome vary among experts. For example, in 1998 the World Health 
Organization (WHO) proposed that the metabolic syndrome criteria require clinical 
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evidence of insulin resistance plus two of the following: (1) obese waist-to-hip ratio or 
BMI >30 kg/m2, (2) raised triglycerides, (3) reduced HDL, (4) raised blood pressure, and 
(5) microalbuminuria. 11, 17   
In 2001, The National Cholesterol Education Program – Adult Treatment Panel 
(NCEP-ATPIII) developed less stringent criteria and categorized metabolic syndrome as 
having any of the following three: (1) obese waist circumference, (2) raised triglycerides, 
(3) reduced HDL, (4) raised blood pressure, and (5) raised fasting blood glucose.18  
Concurrently, the International Diabetes Federation (IDF) developed a metabolic 
syndrome definition similar to ATPIII, with greater emphasis on central obesity.  The 
IDF criterion requires a diagnosis of waist circumference obesity in addition to the 
presence of any two of the following: (1) raised triglycerides, (2) reduced HDL, (3) raised 
blood pressure, and (4) raised fasting blood glucose. 19  In addition, the IDF recommends 
using ethnic-specific obese waist circumference cut-points based on previous research 
and other data sources. 
Using the diagnostic guidelines, approximately 25% of adults in the United State 
have been found to have metabolic syndrome--approximately 47 million American men 
and women. 20, 21  Those with metabolic syndrome are at a 2-fold increased risk for 
cardiovascular disease (CVD) and a 4-fold increase risk for diabetes.21-23 The metabolic 
syndrome thus amplifies the public health significance of diabetes, which already affects 
nearly 20.6 million U.S adults, 20 years of age and older.24  The American Diabetes 
Association estimates that the 2007 medical expenditures and indirect costs for diabetes 
were $174 billion.   
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In subjects with diabetes, 65% have been found to have CVD,25  also a major 
health burden in the United states. An estimated 80.7 million people in the United States 
had CVD in 2005 and over 860,000 deaths occurred in the prior year.26  CVD is the 
leading cause of death for white, black, and Hispanic American adults, according the 
American Heart Association (AHA). AHA projects the 2008 direct and indirect costs of 
managing patients with CVD will be $448.5 billion.  Thus, diabetes, CVD and metabolic 
syndrome are overlapping conditions that contribute significantly to morbidity and 
mortality in the U.S. 
Measuring central obesity is a key factor in the diagnosis and surveillance of 
metabolic syndrome.  Various techniques such as hydrodensitometry weighing, skinfold 
measurements, dual energy X-ray absorptiometry (DEXA), magnetic resonance imaging 
(MRI), and CT, have been used to measure obesity, but are not necessarily appropriate 
for population-based screening of central obesity.27-30  The cost, discomfort, and risk of 
these methods can be prohibitive, or at a minimum, variable and operator-dependent.    
Anthropometric indices, such as BMI, waist circumference (WC), waist-to-hip ratio 
(WHR), and waist-to-height ratio (WHtR),31, 32  are easier to conduct and can be used as 
surrogate measurements for visceral adiposity.30, 33   
Although anthropometric indices of BMI, WC, WHR, and WHtR are currently 
accepted measurements of obesity, experts are not in accord with which obesity indicator 
is the best predictor for metabolic risk factors.17-19, 31  As previously stated, WHO uses 
WHR and both NCEP-ATPIII and IDF use WC as parameters of central obesity.  WHO 
and IDF use BMI as an alternate obesity index when WC is not obtainable.  Although, 
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WHtR is not currently used as a criterion for metabolic syndrome, recent studies suggest 
that WHtR may be a better parameter of central obesity.34-36  
To illustrate the WHtR, a 2006 pilot study using the IDF guidelines compared two 
males with identical WC and BMI measurements but of different heights.37  Their 
glucose test results were considerably different, which the authors inferred could be 
related to a difference in their heights.  As part of their study, the researchers created a 
new measurement called the Index of Central Obesity (ICO).  They defined ICO as an 
obese WHtR cutoff value derived from dividing the national average height by IDF’s 
ethnic and gender-specific obese waist circumference values.  The researchers 
demonstrated that adiposity distribution may be more accurately measured with height as 
part of the equation.  The authors suggest that ICO may be a better measure of central 
obesity than WC because it encompasses the variation of different statures.   
To our knowledge, no studies have been conducted using specific WHtR cutoff 
values to evaluate metabolic syndrome in the adult population in the United States.  This 
study hypothesizes that the novel parameter, ICO, may be better associated with 
metabolic syndrome components in the white, black, and Hispanic adults in the United 
States compared to WC, regardless of age or gender. This study will examine the 
relationships between ICO and factors related to metabolic syndrome using adults 20 
years of age and older from a large nationwide, population-based survey. 
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CHAPTER II 
LITERATURE REVIEW 
 The aim of this study is to determine if ICO is a better index of central obesity for 
the diagnosis of metabolic syndrome as compared to the current WC.  The discussion and 
evaluation of any relationship between ICO and metabolic syndrome components would 
be premature without a comprehensive literature review of the current guidelines and 
central obesity indices.  The literature review will include: (1) an overview of the current 
guidelines for metabolic syndrome diagnosis and their rationale, (2) a review of studies 
analyzing the most common central obesity parameters (BMI, WHR, WC, and WHtR), 
and (3) a summary of the pilot study and their novel parameter, ICO.  
 
2.1 Guidelines for Metabolic Syndrome 
 Attempts to create a unified definition of metabolic syndrome have been made by 
various expert groups.33, 38  The first attempt began in 1998 as WHO responded to the 
epidemic of obesity, diabetes, and cardiovascular disease and developed a preliminary set 
of guidelines to assist in the diagnosis of metabolic syndrome (Table 1).33, 39  However, 
some experts disagree on components of the criteria.  First, measuring insulin resistance 
requires specific laboratory techniques to determine if the individual is in the lowest 
quartile of insulin sensitivity which may be unrealistic in certain settings.33  Second, the 
criterion for high blood pressure is ambiguous.  It is uncertain if the parameter for 
hypertension diagnosis is ≥130mmHg systolic and ≥85mmHg diastolic or if it is 
 7 
≥130mmHg systolic or ≥85mmHg diastolic.38  Third, WHO designated WHR as a 
parameter of central obesity which some argue is not be the best indicator of abdominal 
adiposity.40  
  In 1999, the European Group for the Study of Insulin Resistance (EGIR) 
developed a definition of metabolic syndrome to be used in non-diabetic subjects only,38  
followed by the NCEP ATPIII’s less fastidious definition, which allows for a simple 
application in clinical and epidemiological settings (Table 1).18, 38   The NCEP ATPIII 
definition received criticism for their vague hypertension parameters, similar to WHO’s 
parameters.38  Furthermore, the WC values are gender-specific but do not factor 
racial/ethnic differences despite earlier studies demonstrating racial/ethnic disparities in 
anthropometric measurements and adiposity distribution.41-49  For example, Zhu et al. 
found that BMI levels corresponded to a 5 to 6 centimeter larger WC in white males 
compared to black males, with Hispanic males in between.41   Other studies have 
supporting evidence that blacks tend to have lower volumes of visceral adiposity and 
higher volumes of subcutaneous fat at any given obesity indices compare to their white 
counterparts.43-49 
 For the above reason, IDF developed a new definition for metabolic syndrome 
that was very similar to NCEP ATPIII, but stratified WC cut-points by ethnicity (Table 
1).  IDF’s objective was to create one definition as a diagnostic tool applicable worldwide 
for identifying patients at elevated risk of CVD or Type 2 diabetes.19, 33  Creating a 
universal definition would also allow comparisons of metabolic syndrome prevalence and 
surveillance across all populations.  What distinguishes IDF’s definition of metabolic 
syndrome from NCEP ATPIII’s is the requirement of a central obesity based on ethnic-
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specific WC cut-off values.18, 33  The IDF’s rationale for ethnic-specific WC cut-points is 
based on the findings from previous cross-sectional studies identifying individuals with 
elevated adiposity and elevated risk for CVD at a BMI ≥25 kg/m2 or WHR ≥0.90.33  The 
IDF recommends ethnic-specific WC cut-points should be used irrespective of the 
individual’s place of residence.  However, the IDF recognizes that United States residents 
will likely continue to be screened according to the NCED ATPIII WC cut-points: 102cm 
for male and 88cm for female. 
Table 1.  Definitions of Metabolic Syndrome 
National Cholesterol                      
Education Program Adult                              
Treatment Panel III International Diabetes Federation   World Health Organization
Criteria ≥ 3 components Central obesity                                     
+ ≥ 2 components
Insulin Resistance*                              
+  ≥ 2 components
Obesity WC >40” (men)                                             
WC >35” (women)
Ethnic-specific WC values**                                                 
or BMI >30kg/m2
WHR >0.9 (men)                               
WHR >0.85 (women)                           
or BMI >30kg/m2
Triglycerides ≥150 mg/dL ≥150 mg/dL                                              
or treatment for hypertriglyceridemia
≥150 mg/dL
HDL <40 mg/dL (men)                                   
<50 mg/dL (women)
<40 mg/dL (men)                                   
<50 mg/dL (women)                          
or treatment for low HDL
<35 mg/dL (men)                                  
<40 mg/dL (women)
Blood Pressure ≥ 130/85 mmHg ≥ 130mmHg systolic                            
or ≥85mmHg  diastolic                          
or treament for hypertension
≥ 140/90 mmHg                                       
or treament for hypertension
Fasting Glucose ≥ 110 mg/dL ≥ 100 mg/dL                                            
or diagnosis of                                             
Type II diabetes
N/A
Microalbuminuria N/A N/A urniary albumin >20mg/mL or 
albumin/creatinine ratio >30 mg/g
*Insulin resistance includes glucose intolerance, impaired glucose intolerance, or diabetes
**Europids, Sub-Saharan Africans, Eastern Mediterranean, Middle East (men ≥ 94cm, women ≥ 80cm); South Asian, Chinese, Japanese (men ≥ 90cm, women ≥ 
80cm); USA subjects will use the ATPIII values (men  ≥ 102cm, women ≥88). 
Sources: http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf , http://www.americanheart.org/presenter.jhtml?identifier=4756 , 
http://www.idf.org/webdata/docs/MetS_def_update2006.pdf , http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf  
 
2.2 Studies of Central Obesity Parameters 
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Although specific obesity parameters are not congruent among the different 
definitions of metabolic syndrome, experts concur on other metabolic syndrome 
components: obesity, insulin resistance, dyslipidemia, and hypertension.  As shown in 
Table 1, the metabolic syndrome component of central obesity is identified by 
anthropometric parameters: BMI, WHR, or WC. Currently, some researchers have 
proposed another measurement, WHtR, is a more accurate measurement of central 
obesity for diabetes and CVD risk assessment.34-36, 50-53     
 Before 1980, gender-specific weight-height tables were used to identify obese 
individuals.54  These weight standards changed during 1980-1990 owing to increasing 
rates of obesity and obesity-related diseases.  Based on descriptive statistics of obesity 
distribution and health outcomes, the United States Department of Health and Human 
Services and WHO reported that BMI, weight (kg) divided by height2 (m), was a better 
predictor of body adiposity and a stronger estimator of relative risk for morbidity and 
mortality factors compared to weight-height.54  The National Heart, Lung, and Blood 
Institute suggested that a BMI of ≥30 be used to identify individuals as obese.55 
 Although BMI is a useful estimator of obesity prevalence for large population 
studies, this obesity index has some limitations when estimating risk of CVD and 
metabolic disorders.54  The measurement of body weight does not describe the 
distribution of body adiposity; weight does not discriminate lean body mass from excess 
body fat.  For instance, an athletic person can appear overweight or obese because of 
excess muscle mass.  On the other hand, an older person can appear normal weight due to 
a decrease in muscle mass from influences of aging.  Numerous studies have 
demonstrated that BMI does not estimate central obesity and metabolic related disease as 
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well as other anthropometric measurements, such as WHR, WC, and WHtR.32, 34, 35, 50, 56-
61  Compared to total body fat indicators, central obesity is considered a better surrogate 
measurement of visceral adiposity, which is a risk factor for insulin resistance .12, 62 
 WHR is another commonly used central obese index.  The WHR, a measurement 
of the waist circumference divided by the hip circumference, is recommended by WHO 
during metabolic syndrome screening. 17  The larger the ratio, the greater the tendency 
towards the higher risk android adiposity; the smaller the ratio, the greater the tendency 
towards gynoid adiposity.  To describe the lower risk observed in gynoid phenotypes, 
experts hypothesize larger hip circumferences contain subcutaneous fat that acts as a 
sponge on circulating FFA.12, 14, 62  In theory, this mechanism protect the liver and 
skeletal muscle from high levels of FFA and decreases the potential harmful affect on 
glucose uptake and insulin production.  However, the WHR can be misleading with 
respect to how adiposity is distributed.2  The hip circumference could mask the 
accumulation of abdominal adiposity if the hip circumference increases as well, as shown 
in Figure 1.  In addition, the hip circumference does not differentiate between lean body 
mass and adiposity and therefore, may not accurately account for the inverse correlation 
between subcutaneous fat and insulin resistance.40  Studies have demonstrated that WC 
and WHtR are better predictors of central obesity, more accurate proxies of visceral 
adiposity, and have stronger associations to metabolic syndrome components than 
WHR.32, 53, 63 
Figure 1.  Misleading estimation of abdominal adiposity by WHR 
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Source: Després J, Lemieux, I,  Prud'homme, D. Treatment of obesity: need to focus on high risk 
abdominally obese patients. British Medical Journal. 2001;322:716–720.
 
 Waist circumference is currently the designated indicator for central obesity in 
metabolic syndrome according to the two most common set of criterion:  NCEP ATPIII 
and IDF guidelines.58  Both expert groups use identical WC parameters to identify obese 
adults in the United States: ≥102cm (40 inches) for men and ≥88cm (35 inches) for 
women.18, 19  IDF requires diagnosis of central obesity diagnosis to meet the definition of 
metabolic syndrome definition while NCEP ATPIII suggest individuals may be insulin 
resistant without being classified as centrally obese. IDF also recommends using ethnic-
specific WC cut-points for diagnosis and statistical analysis, stemming from evidence of 
differences of intra-abdominal adiposity among racial/ethnic groups.19, 44   
Although research has shown WC to be a robust measurement of central obesity 
and metabolic disorders,30, 64 some investigators believe height in conjunction with WC is 
better correlated with visceral adiposity and metabolic risk.32, 34, 35, 56  Ashwell and 
colleagues accurately measured 47 individuals’ visceral adiposity via DEXA and found 
the WHtR was the anthropometric index most highly correlated with intra-abdominal fat 
compared to WC, BMI, and WHR (r = 0.83, 0.75, 0.69, and 0.54, respectively).51   
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Other studies comparing noninvasive anthropometric measurements have shown 
WHtR to be the strongest index associated with these metabolic disorders and CVD.32, 50, 
56  Hsieh et al. investigated 8,278 Japanese men and women of various age groups and 
assessed which index of central obesity identified subjects at a higher metabolic risk.50  
Based on previous Asian studies, researchers used a WHtR cut-point of ≥0.50 and found 
that individuals who were considered “normal” weight by BMI standards but centrally 
obese were at a statistically significant elevated risk for metabolic disorders.  In addition, 
researchers reported decreases in BMI and increases in WHtR as age increased.  The 
authors suggest obesity may be distorted by BMI due to muscle loss, while WHtR may be 
more representative of adiposity accumulation as age increases.  Furthermore, female-to-
male ratios of WHtR obesity index were closest to 1 across all age groups compared to 
BMI and WC, implying that the WHtR 0.50 cut-point was effective for both genders.  
Hence, the researchers concluded that a single WHtR may be a better parameter to 
identify metabolic risks across all age groups in both genders.50 
A study conducted by Gracey and colleagues evaluated the WHtR, WC, and BMI 
indices as predictors of CVD in Australian Aborigines.56  They found that obesity cut-
points set at a WHtR ≥ 0.50 and a WC ≥90cm for men and ≥80cm for women were 
slightly better at discriminating for diabetes or CVD compared to BMI ≥22kg/m2.  
However, the authors favored a WHtR parameter as opposed to WC, asserting that a 
single cut-point would allow easier implementation of public health strategies to decrease 
central obesity in both males and females.56   
Using receiver-operating characteristic (ROC) analysis of classifiers, Schneider 
and colleagues demonstrated that an obese WHtR cut-off point between 0.54 and 0.59, 
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was the most sensitive index to predict metabolic syndrome, dyslipidemia, and Type 2 
diabetes in German males and females, in all age groups, compared to WHR, hip 
circumference, WC, and BMI (0.70, 0.63, 0.63, 0.66, respectively).32  The higher WHtR 
cut-point in the German study population (0.54-0.59) compared to other study 
populations (0.50) may be a reflection of the ethnic differences emphasized by the IDF 
regarding WC cut-points.  Accordingly, a recent pilot study attempted to create a WHtR 
parameter that would factor in the ethnic variations of waist circumferences and stature.37 
  
2.3 ICO Pilot Study 
Parikh et al. in a pilot study (discussed previously) designed a new central obesity 
parameter, ICO, with the intention of determining why individuals within a certain ethnic 
group, with identical waist circumferences, have dissimilar risk for metabolic disorders.37  
“The ethnic difference that has led us to lower [WC] cutoffs may be essentially attributed 
to differences in average height”.37  Parikh and colleagues proposed measurement, ICO, 
uses a WHtR derived from the national average height divided by IDF’s WC cut-points. 
The authors hypothesized that ICO correlated better with central obesity than WC, and 
designed an observational study on two individuals of the same ethnic group with the 
same WC.37  Shown in Figure 2, the two subjects’ body compositions are visually 
different with respect to height and girth.  However, their WC and BMI measurements 
were identical, while their ICO, total body fat, and truncal fat measurements varied 
considerably, as reported in Table 2.  In addition, Subject A had normal glucose levels 
while Subject B had hyperglycemia levels of 134 mg/dl.  The authors concluded that their 
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stature variance, accounted for by ICO, influenced the difference in their adiposity 
distribution and glucose tolerance.37  
Figure 2. Subject A (left), 
Subject B (right) 
 
Parameter Subject A Subject B
BMI (kg/m2) 28.8 28.8
WC (cm) 98 98
ICO 0.557 0.645
Total Body Fat (kg) 26.2 15.8
Truncal Fat (kg) 9.5 7.4
TF in TBF (%) 36.11 46.31
Table 2. Comparison of two subjects in the ICO 
pilot study
BMI = Bmody Mass Index; WC = Waist Circumference; ICO 
Index of Central Obesity; TF = Truncal Fat; TBF = Total 
Body Fat  
Source: Reprinted from Medical Hypotheses, 68, Rakesh M, Shashank R, Padmavathy S, and Nalini S, 
Index of Central Obesity – A Novel Parameter, 1272-1275, 2007, with permission from Elsevier 
 
 
2.4 Summary 
The literature demonstrates that WHtR may be a better parameter for identifying 
those at an elevated risk for metabolic disorders compared to WC, BMI, or WHR.  
Proponents for the WHtR emphasize the simplicity of using a single WHtR value to 
diagnose central obese individuals irrespective of age or gender.  The WHtR cut-points of 
ICO were used in these studies as proposed by expert organizations and/or from ROC 
analysis. The discriminating factor between the WHtR evaluated in previous studies and 
the ICO evaluated in the pilot study is that the ICO assumes the average national height 
will account for ethnic differences and measure central obesity more accurately.  Based 
on the literature, this study will analyze the relationship between ICO and metabolic 
syndrome components in white, black, and Hispanic adults in the United States. 
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CHAPTER III 
METHODS AND PROCEDURES 
  
3.1 Study Purpose 
This cross-sectional study was designed to: (1) determine if the Index of Central 
Obesity has a stronger association with metabolic syndrome components compared to 
waist circumference among the white, black, and Hispanic adults in the United States; (2) 
determine race/ethnic specific differences with respect to the association between ICO 
and the metabolic syndrome components; and (3) assess if the relationship between ICO 
and metabolic syndrome components and varies by age.  
3.2 Data Source  
The data that was used in the study were obtained from the National Center for 
Health Statistics’ (NCHS) National Health and Nutrition Examination Survey 
(NHANES).  The NCHS was created in 1960 following Congress’ National Health 
Survey Act of 1956, which required the collection of information to monitor illness and 
disabilities of the United States civilian non-institutionalized population.  The 
nationwide, population-based survey collects data via interviews, clinical tests, 
measurements, and physical examinations.   
From 1960 to 1970, the National Health Examination Surveys (NHES I, II, and 
III) were limited to specific age groups and certain illnesses.  For example, NHES I was 
centered on chronic disease and adults 18-79 years of age, while NHES II and NHES III 
were centered on growth and development of children 6-11 years of age and 12-17 years 
of age, respectively. Stemming from the 1967 Senate hearings on Hunger in America, a 
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nutrition component was added to the survey due to links between dietary intake and 
disease.  Starting in 1971, the name of the survey was changed to the National Health and 
Nutrition Examination Survey (NHANES).  By 1999, NHANES evolved into a 
continuous annual survey of all ages to allow pertinent programmatic changes to 
accommodate emerging public health needs.  
This study used data from the NHANES 2005-2006 interviews and examinations.  
The NHANES 2005-2006 survey design was a stratified, multistage probability sample 
made to represent the general US population. The multiple sample stages included: (1) 
selection of counties or small groups of counties, (2) block or group of blocks within 
those counties, (3) households within those blocks, and (4) one or more participants 
within those households.  The 2005-2006 survey used higher sampling rates for low-
income persons, persons 60+ years of age, African Americans, and Mexican Americans 
to increase the reliability and accuracy of statistical analysis for these groups.   
During NHANES in-home interview portion, eligible participants signed consent 
forms and interviewers administered health questionnaires.  Computer-Assisted Personal 
Interview technology was used to record participants’ answers to the demographic, 
socioeconomic, dietary, and health-related questions.  The health examination portion 
was conducted in Mobile Examination Centers (MECs) by professional medical teams. 
The examination collected health and nutrition information from physical exams, dietary 
interviews, and laboratory tests.  In total, the NCHS surveyed 10,348 individuals of all 
ages between January 2005 and December 2006.   
After the interview and examination data were collected and processed, The 
Centers for Disease Control and Prevention (CDC) posted the results in a publicly 
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accessible SAS transport file format on their website 
(http://www.cdc.gov/nchs/nhanes.htm).  All information collected from the NHANES 
2005-2006 for this study was secondary, de-identified data and downloaded into SPSS® 
15.0.   For our research purposes, population delimitations were established to include 
only white, black, and Hispanic American adults, 20 years of age and older, with waist 
and height measurements documented.  Of the 10,348 subjects in NHANES 2005-2006, 
only 1,919 female and 1,777 males met the criteria for this study. 
 
3.3 Study Variables 
(3.3.a.) Demographic Variables 
Demographic/socioeconomic variables included in this study were age, gender, 
race/ethnicity, education, income, and insurance.  Age was recoded into categories, of 
young, middle, and older age groups (AGEGP: 1 = 20 to 39 years of age, 2 = 40 to 59 
years of age, 3 = 60 or older).  Analysis was stratified by gender (1 = male, 2 = female) 
due to differences in obesity parameters and clinical parameters between the sexes.  
Race/ethnicity was recoded as “1” for Non-Hispanic White, “2” for Non-Hispanic Black, 
and “3” for Mexican American and other Hispanic.  Other variables that were used in this 
study include education (EDU: 1 = less than high school, 2 = high school degree or GED, 
3 = more than a high school education), annual household income (INC: 1 = $0-$19,999, 
2 = $20,000-$44,999, 3 = $45,000-$74,999, 4 = $75,000 or more),  health insurance 
coverage (INS: 1 = yes, 0 = no), and Medicare or Medicaid coverage (GOVINS: 1 = yes, 
0 = no). 
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(3.3.b.) Anthropometric Variables 
Anthropometric measurements necessary to identify obese versus non-obese 
subjects included height, weight, and waist circumference.  During the NHANES 
physical examination, standing height (HT) was determined at the maximum vertical size 
measured in centimeters via a fixed stadiometer with a vertical backboard and moveable 
headboard.65 Waist circumference (WC) was measured in centimeters from the horizontal 
line above the uppermost lateral border of the right ilium.65  To capture those with 
abdominal obesity, WC was transformed into an obese waist circumference variable 
(MS_ObeseWC).  MS_ObeseWC was coded as “1” indicating obesity if males measured 
at least 102cm or if females measured at least 88cm, in accordance with IDF guidelines.19  
Subjects who did not have an obese waistline were coded as “0”.  Waist-to-Height Ratio 
(WHtR) was computed by dividing the WC by the HT.  To classify those with central 
obesity, an ICO status variable (MS_ObeseICO) was created by using parameters that 
were used in a previous pilot study.37  Similar to the pilot study, the ICO parameters were 
computed by taking NHANES 2005-2006 average height of the American male adult, 
176cm, and the American female adult, 162cm, divided by the IDF obese WC gender 
cutoffs (≥102cm for men, ≥88cm for women). MS_ObeseICO was coded as “1” if the 
WHtR was at or above the cutoff of 0.58 for men and 0.54 for women. Those with 
WHtR’s below these values were not considered obese and were coded as “0”.   BMI 
(Obese_BMI), was calculated as weight(kg)/height2 (m) and coded as obese if values 
were at or above 30. 
(3.3.c.) Behavioral Variables 
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Variables used to describe behavioral characteristics were cigarette smoking, alcohol 
use, and physical activity.  “Cigarette Smoker” was defined as someone who self reported 
smoking 100 or more cigarettes in their lifetime. “Alcohol Use” was defined as the 
average weekly alcohol consumption, derived from the subjects’ responses to drinking 
questions.  Average weekly alcohol consumption was calculated by multiplying the 
number of days a subject drinks (per week, month, or year), by the average number of 
drinks during those days, by the unit of time (52 weeks or 12 months or 1 year), and 
dividing by 52 weeks.  “Physical Activity” was determined using the number of times 
subjects self-reported specific physical activities at a moderate or vigorous level in the 
past 30 days.  Physical activities included: aerobics, baseball, basketball, bicycling, 
bowling, dance, fishing, football, gardening, golf, hiking, hockey, hunting, jogging, 
kayaking, push-ups, racquetball, rollerblading, rowing, running, sit-ups, skating, skiing 
cross country, skiing downhill, soccer, softball, stair climbing, stretching, swimming, 
tennis, treadmill, volleyball, walking, weight lifting, yard work, boxing, frisbee, 
horseback riding, martial arts, wrestling, yoga, cheerleading/gymnastics, rope jumping, 
skateboarding, surfing, trampoline jumping, and other. 
(3.3.d.) Medical History Variables 
Medical history included variables of both individual and family history of diabetes, 
heart disease, and stroke.  Subjects who were previously diagnosed with diabetes or a 
stroke were coded as having a history of diabetes or a history of a stroke respectively.  
Subjects who were previously diagnosed with coronary heart disease, angina, or heart 
attack were coded as having a history of heart disease. The presence of family history 
included an occurrence of diabetes or heart attack in a close biological family member.  
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(3.3.e.) Clinical Variables 
Clinical variables essential to metabolic syndrome components included systolic and 
diastolic blood pressure, serum triglyceride, HDL levels, and fasting blood glucose. For 
this study, the IDF definition and cutoffs for metabolic syndrome components were used 
with some exception. Systolic and diastolic blood pressure readings were administered 
one to four times during the examination.  The raised blood pressure variable 
(MS_HighHBP) was an average of both the systolic and diastolic blood pressure 
readings.  If the systolic average was ≥135mmHg or the diastolic average was ≥85mmHg 
or the subject reported taking hypertension medication, they were coded as having raised 
blood pressure.  Individuals with triglyceride levels ≥150mg/dL were categorized as 
having raised triglycerides (MS_HighTri).  However, subjects on a cholesterol medicine 
regimen were not regarded as having raised triglycerides due to lack of information 
concerning the cholesterol type targeted. Subjects with HDL levels below 40mg/dL for 
men and 50mg/dL for women were defined as having abnormal reduced HDL 
(MS_LowHDL).  The same omission of those on a cholesterol medicine regimen applied 
with this metabolic syndrome component.  Individuals with fasting blood glucose levels 
recorded as ≥100mg/dL or previously diagnosed diabetes were identified as having raised 
fasting blood glucose (MS_HighGlucose). 
 
 
3.4 Statistical Analysis 
 
 All statistical analysis was conducted using SPSS® 15.0.  Tables and figures were 
created using both SPSS® 15.0 and Microsoft® Office Excel 2003.  All analysis was 
gender specific due to gender differences in body composition and blood lipid profile.   
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Characteristics of study populations were evaluated using demographic variables 
(age, education level, income level, insurance status, Medicaid/Medicare status), 
behavioral factors (cigarette smoking history, alcohol use, physical activity), medical 
history (personal history of diabetes, heart disease, stroke; family history of diabetes, 
heart attack), anthropometric measurements (waist circumference, height, waist-to-height 
ratio, obese waist circumference, obese ICO, and obese BMI), and clinical measurements 
(raised blood pressure, raised triglycerides, reduced HDL, raised fasting blood glucose). 
For both males and females, characteristics were analyzed in three different formats: (1) 
differences between racial/ethnic subgroups, (2) differences between obese and not obese 
subgroups, and (3) differences between racial/ethnic subgroups of the obese study 
population. Differences of continuous variables among the subgroups were tested at the 
0.05 significance level using one-way analysis of variance (ANOVA) in racial/ethnic 
group stratification (white, black, Hispanic) and independent t-tests in ICO status 
stratification (obese/not obese).  Results were reported in terms of means and standard 
deviations (µ ± SD).  Differences between categorical variables among the subgroups 
were tested at the 0.05 significance level using chi-square and reported as a proportion of 
the study population.   
 To evaluate the strength of the relationship between the independent variable 
(ICO) and the dependent variables (metabolic syndrome components), correlation 
analyses were performed.  To measure the strength of association between ICO and 
metabolic syndrome components among races/ethnicities, a two-tailed partial correlation 
test using Pearson’s correlation analyses were conducted controlling for age.  To evaluate 
the strength of relationship between the same independent and dependent variables with 
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respect to age, a two-tailed bivariate correlation analyses was performed using 
Spearman’s Rho correlation coefficient in each age group (20-39, 40-59, 60+) stratified 
by race/ethnic group.   Correlations that were statistically significant were noted at both 
the 0.01 level and the 0.05 level of probability. 
 Odds ratios (OR) were calculated at the 95% confidence level to quantify the 
association of central obesity and with each metabolic syndrome component. Univariate 
and multivariate logistic regression were performed to determine association between 
dependent and independent variables. The OR for whites, blacks, and Hispanics was 
calculated.  In the multivariate regression analyses, statistical adjustments were made for 
age, education level, income level, health insurance status, history of cigarette smoking, 
alcohol use, and physical activity.  In both univariate and multivariate analysis, WC and 
ICO were analyzed separately as the independent variable to allow estimations of OR 
differences.  The 95% confidence level was used to determine statistical significance. 
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CHAPTER IV 
RESULTS 
 
4.1 Basic Characteristics  
 The basic demographic factors, anthropometric measurements, behavioral factors, 
medical history, and clinical factors of the eligible males and females are shown in Table 
3 and Table 4 respectively.  White, black, and Hispanic subjects were statistically 
different with respect to age, education level, income level, insurance status, and 
Medicare/Medicaid status.  Hispanic men and women were younger, had a lower 
education level, and had the highest uninsured rates compared to their white and black 
counterparts (p<0.01).  White males and females tended to be older and at a higher 
socioeconomic status than their black and Hispanic counterparts (p<0.01).   
 Except for male BMI, all anthropometric measurements were statistically 
different between white, black, and Hispanic subjects.  Among males, whites had larger 
waists (mean, 103cm) and higher rates of abdominal obesity (50%) than blacks and 
Hispanics (p<0.05).  Among females, blacks had larger waist measurements (mean, 
100cm) and higher rates of abdominal obesity (73%) compared to whites and Hispanics 
(p<0.001).  In both men and women, Hispanics had the shortest stature among the 
races/ethnicities (p<0.01).    
 Racial/ethnic differences were evident with respect to the history of heart disease 
among males and the history of diabetes and family history of diabetes among males and 
females (p<0.05).  Compared to white subjects, blacks and Hispanics were twice as likely 
to have diabetes (p<0.001).  Within the male population, whites were at least 1.5 times 
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more likely to have a history of heart disease among the three races/ethnicities (p<0.05).  
Racial/ethnic differences in all other medical history were not statistical significant.    
 Racial/ethnic differences in rates of metabolic syndrome components (raised 
blood pressure, raised triglycerides, reduced HDL, and raised fasting blood glucose) were 
statistically significantly at the 0.01 level of probability with exception to glucose levels 
within male subjects (p=0.08).  Raised blood pressure was more prevalent in blacks and 
affected 51% of black males and 47% of black females (p<0.001).  Dyslipidemia and 
hyperglycemia were more common in Hispanics compared to whites and blacks.  In 
males, Hispanics were approximately 2.2 times more likely to have raised triglycerides 
and 2.3 times more likely to have reduced HDL levels than black males (p<0.001).  In 
females, Hispanics were 1.5 times more likely to have raised fasting blood glucose than 
whites, and 2.3 times more likely to have raised triglycerides and 1.6 times more likely to 
have reduced HDL than blacks (p<0.001).  
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White                             
(n = 1078)
Black                        
(n = 460)
Hispanic                     
(n = 239)
p-value
*
53 ± 19 48 ± 17 47 ± 18 <.001
Education:           < high school 17.1% 29.1% 42.3% <.001
high school 26.3% 27.6% 17.2%  
> high school 56.7% 43.3% 40.6%  
Income:                     <$20,000 16.9% 18.8% 17.0% 0.008
$20,000-$44,999 28.6% 34.3% 38.3%  
$45,000-$74,999 24.3% 23.6% 24.3%  
>$75,000 30.2% 23.3% 20.4%  
84.7% 77.2% 74.9% <.001
34.8% 25.0% 23.0% <.001
62.4% 53.7% 51.5% <.001
6 ± 11 4 ± 9 5 ± 8 0.003
11 ± 15 13 ± 16 15 ± 28 0.017
7.7% 15.9% 15.7% <.001
12.4% 8.9% 6.7% 0.012
4.1% 4.6% 3.3% 0.742
34.1% 47.8% 51.1% <.001
15.8% 12.1% 11.5% 0.074
102.7 ± 15.0 100.0 ± 16.9 101.1 ± 14.3 0.005
176.5 ± 7.2 177.2 ± 7.4 171.4 ± 7.0 <.001
0.58 ± .09 0.56 ± .09 0.59 ± .08 <.001
49.9% 43.3% 42.3% 0.015
48.6% 40.7% 49.4% 0.011
31.6% 37.8% 33.1% 0.062
43.7% 50.7% 32.6% <.001
42.3% 24.8% 54.4% <.001
23.7% 13.1% 30.3% <.001
29.4% 31.7% 36.8% 0.075Raised Fasting Blood Glucose
6
Obese BMI 
8
Raised Blood Pressure
6
Raised Triglycerides
6
Reduced HDL
6
WtHR
1, 5 
Obese Waist Circumference
6
Obese ICO
7
Family History of Heart Attack
Waist Circumference
1
 (cm)
Height
1
 (cm) 
Table 3.  Characteristics of the Male Study Population by Race,                                                   
NHANES 2005-2006
Alcohol Use
3
Physical Activity
4            
Age (years)
1
Covered by Insurance
Covered by Medicare/Medicaid
History of Smoking
2
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White                             
(n = 1120)
Black                      
(n = 503)
Hispanic                  
(n = 296)
p-value
*
50 ± 20 46 ± 17 44 ± 17 <.001
Education:               < high school 13.2% 25.8% 33.4% <.001
high school 26.3% 19.9% 27.4%  
> high school 60.5% 54.3% 39.2%  
Income:                      <$20,000 17.6% 27.7% 24.3% <.001
$20,000-$44,999 27.3% 30.2% 35.1%  
$45,000-$74,999 25.3% 24.0% 20.3%  
> $75,000 29.8% 18.2% 20.3%  
89.6% 82.9% 81.0% <.001
31.6% 31.4% 22.0% 0.004
47.7% 33.5% 33.8% <.001
2 ± 4 2 ± 9 1 ± 2 0.036
12 ± 17 13 ± 14 12 ± 13 0.929
7.1% 13.1% 14.5% <.001
6.2% 6.4% 3.0% 0.094
3.7% 4.0% 3.0% 0.792
38.6% 55.5% 57.7% <.001
17.1% 12.6% 14.1% 0.061
94.9 ± 16.1 99.8 ± 17.4 96.1 ± 14.4 <.001
162.8 ± 6.7 162.4 ± 6.5 158.2 ± 6.5 <.001
0.58 ± 0.10 0.61 ± 0.11 0.61 ± 0.10 <.001
63.5% 73.2% 69.6% <.001
64.5% 72.0% 76.0% <.001
32.4% 53.7% 40.9% <.001
36.1% 47.1% 25.7% <.001
39.1% 17.6% 41.3% <.001
24.0% 21.7% 35.8% <.001
18.8% 25.4% 28.4% <.001Raised Fasting Blood Glucose
6
Obese ICO
7
Obese BMI 
8
Raised Blood Pressure
6
Raised Triglycerides
6
Family History of Diabetes
Family History of Heart Attack
Waist Circumference
1
 (cm)
Reduced HDL
6
Table 4.  Characteristics of the Female Study Population by Race,                                              
NHANES 2005-2006
History of Stroke
Age (years)
1
Covered by Insurance
Covered by Medicare/Medicaid
Alcohol Use
3
Physical Activity
4           
History of Diabetes
History of Heart Disease
History of Smoking
2
* p-values for continuous variables and categorical variables are from oneway ANOVA and chi-square, respectively;  (1) µ ± SD;  (2) 
Smoked at least 100 cigarettes in lifetime;  (3) Average number of alcohol drinks consumed per week,  (4) Number of moderate or vigourous 
activites performed in the past 30 days;  (5) Waist-to-Height Ratio = waist circumference (cm) / height (cm);  (6) Metabolic Syndrome 
Components for women: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides (≥150mg/dl), reduced HDL 
(<50 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis), obese waist circumference (≥88 cm);  (7) Index of 
Central Obesity for women = waist circumference cutoff / average national height > 0.54;  (8)  Obese Body Mass Index (BMI) >  30
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Age-specific (young adults, middle-aged adults, and older adults) prevalence of 
ICO in the eligible men and women are shown in Figure 3 and Figures 4, respectively. A 
shown, a positive linear relationship is evident: as age increases, the proportion of ICO 
cases increases.  Figure 3 shows the prevalence of ICO increases nearly 50% as age 
increases from the youngest to the oldest group of the obese males.  Figure 4 shows a 
smaller increase (25%) of ICO prevalence between the youngest and oldest group of 
obese females.  Although the increase is not as substantial in the females, young female 
adults are twice as likely to be obese as compared to their male counterparts.   
Figure 3.  Index of Central Obesity > 0.58 in Adult Males by Age Group, 
NHANES 2005-2006
31.3%
47.7%
59.2%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
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70.0%
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P<0.05 
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Figure 4.  Index of Central Obesity > 0.54 in Adult Females by Age Group, 
NHANES 2005-2006
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 In Figure 5 and Figure 6, comparison of the rate of ICO in white, black, and 
Hispanics in the males and females are shown respectively.  In men, no differences in 
obesity rates were observed in white and Hispanic, while black men presented with 
approximately 10% smaller rates of ICO compared to white and Hispanic men.  In 
women, significant different rates of ICO are apparent with white females having fewer 
subjects with ICO.  Irrespective of race/ethnicity, obesity was more prevalent across 
white, black, and Hispanic females (over 60%) versus the males (under 50%). 
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Figure 5.  Rate of ICO of White, Black, and Hispanic Men, 
NHANES 2005-2006 
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Figure 6.  Rate of ICO of White, Black, and Hispanic Women, 
NHANES 2005-2006
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 To further delineate differences between obese and non-obese subjects, the study 
population was stratified by ICO parameters defined by a WHtR at or above 0.58 for 
males and 0.54 for females.  Differences in characteristics between the male obese (47%) 
and non-obese (53%) subjects are shown in Table 5 and the female obese (68%) and non-
obese (32%) subjects are shown in Table 6.  With exception of income in males, obese 
and non-obese subjects differed with respect to all demographic variables that were 
studied (p<0.05).  The obese subjects tended to be older, less educated, and more likely to 
have health insurance.  
 As expected, anthropometric measurements varied between obese and non-obese 
subjects (p<0.001).  In males, 91% of obese males had an obese waist circumference 
(>102), averaging 23cm larger than non-obese males.  In females, 94% had an obese 
waist circumference (>88cm) and were an average 25cm larger than the non-obese.  A 
smaller proportion of ICO obese subjects were considered BMI obese: 67% of central 
obese males and 57% of central obese females had BMI >30.   
Fewer non-obese subjects reported a history of diabetes, heart disease, stroke, 
family history of diabetes, and family history of heart attacks compared to obese subjects 
(p<0.05).   Obese males and females were approximately 3 times more likely to have a 
history of diabetes, 2 times more likely to have a history of heart disease, and 3 times 
more likely to have a history of stroke than their non-obese counterparts (p<0.001). As 
anticipated, obese subjects demonstrated higher rates of metabolic syndrome 
components.   In males, obese subjects were nearly 2 times more likely to have raised 
blood pressure, raised triglycerides, reduced HDL, or raised fasting blood glucose in 
relation to non-obese subjects (p <0.001). In females, obese subjects were approximately 
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2 times more likely to have either raised blood pressure or reduced HDLS and 
approximately 3 times more likely to have raised triglycerides or raised fasting blood 
glucose compared to non-obese subjects (p<0.001). 
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Not Obese                     
(n = 948)
Obese                     
(n = 829)
p-value
*
47 ± 19 56 ± 17 <.001
Education:           < high school 22.0% 25.3% 0.021
high school 23.8% 27.1%
> high school 54.1% 47.5%
Income:                     <$20,000 17.0% 17.8% 0.832
$20,000-$44,999 30.8% 32.1%
$45,000-$74,999 24.3% 23.8%
>$75,000 27.9% 26.2%
77.4% 86.0% <.001
23.4% 39.0% <.001
58.1% 59.3% 0.317
6 ± 12 4 ± 9 <.001
11 ± 18 13 ± 16 0.159
6.1% 16.5% <.001
6.5% 15.6% <.001
2.1% 6.4% <.001
34.3% 46.5% <.001
12.5% 16.3% 0.015
91 ± 9 114 ± 12 <.001
177 ± 7 175 ± 8 <.001
0.51 ± .05 0.65 ± .06 <.001
8.8% 91.1% <.001
3.9% 67.2% <.001
32.7% 56.9% <.001
28.7% 51.5% <.001
15.6% 28.9% <.001
23.2% 39.9% <.001
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7
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7
WtHR
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2
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2
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* p-values for continuous variables and categorical variables are from independent t-test and chi-square, respectively;  
(1) ICO Status = obese (> 0.58) or not obese (< 0.58);  (2) µ ± SD;  (3) Smoked at least 100 cigarettes in lifetime;  (4) 
Average number of alcohol drinks consumed per week;  (5) Number of moderate or vigourous activites performed in 
the past 30 days;  (6) Waist-to-Height Ratio = waist circumference (cm) / height (cm);  (7) Metabolic Syndrome 
Components for men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides 
(≥150mg/dl), reduced HDL (<40 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis), obese 
waist circumference (≥102 cm);  (8) Obese Body Mass Index (BMI) > 30
Obese Waist Circumference
7
Obese BMI 
8
Table 5.  Characteristics of the Male Study Population                                                                                                                                          
by Index of Central Obesity (ICO)
1
,  NHANES 2005-2006
Alcohol Use
4
Physical Activity
5         
Age (years)
2
Covered by Insurance
Covered by Medicare/Medicaid
History of Smoking
3
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Not Obese                    
(n = 610)
Obese                   
(n = 1309)
p-value
*
43 ± 18 50 ± 19 <.001
Education:               < high school 13.5% 22.5% <.001
high school 20.9% 26.6%
> high school 65.7% 50.9%
Income:                      <$20,000 18.2% 22.7% <.001
$20,000-$44,999 23.6% 31.8%
$45,000-$74,999 21.9% 25.3%
> $75,000 36.3% 20.2%
84.4% 87.5% 0.038
20.2% 34.7% <.001
43.7% 40.9% 0.140
3 ± 8 2 ± 4 <.001
12 ± 15 13 ± 16 0.469
3.6% 12.7% <.001
3.1% 7.0% <.001
1.5% 4.7% <.001
37.2% 50.1% <.001
12.2% 17.0% 0.004
79 ± 6 104 ± 13 <.001
163 ± 7 161 ± 7 <.001
0.49 ± .04 0.65 ± .08 <.001
8.5% 94.2% <.001
0.5% 57.4% <.001
22.6% 44.2% <.001
14.1% 43.1% <.001
13.1% 30.8% <.001
10.0% 27.6% <.001
* p-values for continuous variables and categorical variables are from independent t-test and chi-square, respectively;  (1) 
ICO Status = obese (> 0.54) or not obese (< 0.54);  (2) µ ± SD;  (3) Smoked at least 100 cigarettes in lifetime;  (4) 
Average number of alcohol drinks consumed per week;  (5) Number of moderate or vigourous activites performed in the 
past 30 days;  (6) Waist-to-Height Ratio = waist circumference (cm) / height (cm);  (7) Metabolic Syndrome Components 
for women: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides (≥150mg/dl), 
reduced HDL (<50 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis), obese waist 
circumference (≥88 cm);  (8) Obese Body Mass Index (BMI) > 30
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Family History of Heart Attack
Raised Fasting Blood Glucose
7
Obese BMI 
8
Raised Blood Pressure
7
Raised Triglycerides
7
Reduced HDL
7
Table 6.  Characteristics of the Female Study Population                                                                                                                                          
by Index of Central Obesity (ICO)
1
,  NHANES 2005-2006
History of Stroke
Age (years)
2
Covered by Insurance
Covered by Medicare/Medicaid
Alcohol Use
4
Physical Activity
5          
History of Diabetes
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 To define racial/ethnic variations among the obese study population, the same 
descriptive variables were stratified by white, black, and Hispanics. Table 7 and Table 8 
show the basic description of the 829 obese males (63% white, 23% black, 14% 
Hispanic) and the 1309 obese females (55% whites, 28% blacks, 17% Hispanics) in that 
order.  A majority of studied characteristics were significantly different between the three 
obese subgroups.  The average physical activity, rate of heart disease, rate of stroke, 
family history of heart attacks, and rate of hyperglycemia did not vary between white, 
black, and Hispanic obese subjects (p>0.05).  In addition, income and WHtR did not vary 
among the males while alcohol use did not vary among the females (p>0.05). 
 White, black, and Hispanic obese subjects were statistically different with respect 
to demographic factors.  On stratifying for ICO, white subjects remained older, more 
educated, and more likely to have health insurance among all three races/ethnicities 
(p<0.01)   Hispanic subjects remained younger, with the least education, and least likely 
to have health insurance (p<0.01). 
 Body composition differences were significant between the white, black, and 
Hispanic obese subjects (p<0.05) with exception to the males’ WHtR.  Among the three 
subgroups, obese black subjects were inclined to have larger anthropometric 
measurements while obese Hispanic subjects tended to be smaller in stature and waist 
measurements.  In addition, variation in central obesity prevalence depended on the type 
of indicator.  For example, 20% of Hispanic males with an obese ICO were not obese 
according to WC measurements compared to only 5% of black males. 
 Racial/ethnic differences among the obese subjects were observed in the history 
of diabetes, history of heart disease, and family history of diabetes (p <0.05).  Among the 
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three races/ethnicities, heart disease was most prevalent in obese white males and females 
while diabetes was most prevalent in obese black males and obese Hispanic females.  The 
rate of metabolic syndrome components, with exception to blood glucose levels, varied 
between the obese white, black, and Hispanic (p<0.001) as well. Obese black subjects 
had higher rates of raised blood pressure while obese Hispanic subjects had higher rates 
of raised triglycerides and reduced HDL levels. 
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White                             
(n = 524)
Black                        
(n = 187)
Hispanic                     
(n = 118)
p-value
*
58 ± 17 51 ± 17 50 ± 17 <.001
Education:           < high school 19.8% 27.8% 45.8% <.001
high school 27.5% 31.0% 19.5%
> high school 52.7% 41.2% 34.7%
Income:                     <$20,000 17.5% 18.7% 17.9% 0.259
$20,000-$44,999 29.8% 35.2% 37.5%
$45,000-$74,999 23.9% 22.0% 26.8%
> $75,000 28.8% 24.2% 17.9%
89.7% 81.3% 77.1% <.001
43.1% 32.1% 31.4% 0.005
63.9% 50.3% 53.4% 0.002
5 ± 10 3 ± 6 3 ± 6 0.036
12 ± 17 14 ± 15 13 ± 12 0.630
12.9% 23.9% 20.9% 0.001
17.7% 13.9% 8.5% 0.033
5.5% 9.6% 5.1% 0.120
42.0% 56.4% 50.4% 0.003
18.0% 13.8% 13.0% 0.255
114 ± 12 115 ± 12 111 ± 12 0.003
175 ± 7 177 ± 8 170 ± 7 <.001
0.65 ± 0.06 0.66 ± 0.06 0.65 ± 0.07 0.829
92.2% 95.2% 79.7% <.001
62.6% 81.8% 64.4% <.001
57.8% 65.8% 39.0% <.001
54.0% 34.4% 67.3% <.001
29.9% 17.8% 42.1% <.001
38.5% 41.7% 43.2% 0.550Raised Fasting Blood Glucose
6
Obese BMI
 7
Raised Blood Pressure
6
Raised Triglycerides
6
Reduced HDL
6
WtHR
1, 5 
Obese Waist Circumference
6
Family History of Heart Attack
Waist Circumference
1
 (cm)
Height
1
 (cm) 
Table 7.  Characteristics of the Obese Male Study Population by Race,                                                                                                       
ICO > 0.58, NHANES 2005-2006
Alcohol Use
3
Physical Activity
4            
Age (years)
1
Covered by Insurance
Covered by Medicare/Medicaid
History of Smoking
2
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* p-values for continuous variables and categorical variables are from oneway ANOVA and chi-square, respectively;  (1) µ ± SD;  (2) 
Smoked at least 100 cigarettes in lifetime;  (3) Average number of alcohol drinks consumed per week,  (4) Number of moderate or 
vigourous activites performed in the past 30 days;  (5) Waist-to-Height Ratio = waist circumference (cm) / height (cm);  (6) Metabolic 
Syndrome Components for men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides (≥150mg/dl), 
reduced HDL (<40 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis), obese waist circumference (≥102 cm);  
(7)  Obese Body Mass Index (BMI) >  30
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White                             
(n = 722)
Black                      
(n = 362)
Hispanic                  
(n = 225)
p-value
*
52 ± 20 48 ± 17 45 ± 17 <.001
Education:               < high school 15.5% 27.3% 37.3% <.001
high school 29.1% 20.7% 28.0%
> high school 55.4% 51.9% 34.7%
Income:                      <$20,000 19.0% 28.4% 25.2% 0.001
$20,000-$44,999 30.5% 31.6% 36.7%
$45,000-$74,999 27.0% 24.1% 21.4%
> $75,000 23.5% 15.8% 16.7%
92.1% 83.4% 79.5% <.001
37.7% 35.1% 24.4% 0.001
47.2% 33.1% 33.3% <.001
2 ± 4 1 ± 5 1 ± 3 0.092
13 ± 18 13 ± 15 12 ± 12 0.757
10.0% 14.4% 18.6% 0.002
8.2% 6.9% 3.1% 0.033
5.1% 4.4% 3.6% 0.602
43.4% 58.2% 58.6% <.001
18.7% 14.2% 15.7% 0.162
104 ± 13 107 ± 14 101 ± 12 <.001
162 ± 7 162 ± 6 158 ± 6 <.001
0.64 ± .08 0.66 ± .09 0.64 ± .08 <.001
94.0% 96.7% 90.7% 0.010
50.0% 74.3% 53.8% <.001
44.6% 53.6% 28.0% <.001
51.9% 21.4% 48.4% <.001
30.4% 25.7% 39.8% 0.002
25.3% 29.6% 31.6% 0.117
* p-values for continuous variables and categorical variables are from oneway ANOVA and chi-square, respectively;  (1) µ ± SD;  (2) 
Smoked at least 100 cigarettes in lifetime;  (3) Average number of alcohol drinks consumed per week,  (4) Number of moderate or vigourous 
activites performed in the past 30 days;  (5) Waist-to-Height Ratio = waist circumference (cm) / height (cm);  (6) Metabolic Syndrome 
Components for women: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides (≥150mg/dl), reduced HDL 
(<50 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis), obese waist circumference (≥88 cm);  (7)  Obese Body 
Mass Index (BMI) >  30
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WtHR
1, 5 
Obese Waist Circumference
6
Table 8.  Characteristics of the Obese Female Study Population by Race,                                                          
ICO > 0.54, NHANES 2005-2006
History of Stroke
Age (years)
1
Covered by Insurance
Covered by Medicare/Medicaid
Alcohol Use
3
Physical Activity
4           
History of Diabetes
History of Heart Disease
History of Smoking
2
Family History of Diabetes
Family History of Heart Attack
Waist Circumference
1
 (cm)
Reduced HDL
6
Raised Fasting Blood Glucose
6
Obese BMI 
7
Raised Blood Pressure
6
Raised Triglycerides
6
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4.2 Correlation Between Central Obesity Indicators & Metabolic Syndrome 
Components 
 
 The degree of linear correlation between ICO and four metabolic syndrome 
components was assessed in males and females. The results of the correlation analysis 
between ICO and metabolic syndrome components, stratified by race/ethnicity and 
adjusted for age, are shown in Table 9 (males) and Table 10 (females).   Raised blood 
pressure and raised fasting blood glucose were positively correlated with ICO among all 
three races/ethnicities, but not significant in Hispanic subjects (p>0.05).  Raised 
triglycerides and reduced HDL were positively associated with ICO and significant in all 
three racial/ethnic groups (p <.05).  In males, an ICO in whites, blacks, and Hispanics had 
a higher degree of correlation with raised triglycerides, raised blood pressure, and 
reduced HDL, respectively.  The ICO of obese white, black, and Hispanic females had a 
higher degree of correlation with raised triglycerides, reduced HDL, and raised 
triglycerides, in that order.   
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White                             
(n = 524)
Black                        
(n = 187)
Hispanic                     
(n = 460)
.196** .214** .052
.147** .143** .089
.251** .183** .234**
.172** .127** .253**
Table 9.  Correlation with ICO
1
 and Metabolic Syndrome Components
2
,                                                                                    
Age-Adjusted, Obese Male Study Population, NHANES 2005-2006
Significance of association was measured using a two-tailed, partial correlation while controlling for age.
Raised Fasting Blood Glucose
2
Raised Blood Pressure
2
Raised Triglycerides
2
Reduced HDL
2
Metabolic Syndrome 
Components
(2) Metabolic Syndrome Components for men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking 
meds), raised triglycerides (≥150mg/dl), reduced HDL (<40 mg/dl), raised fasting blood glucose (≥100 mg/dl or 
Type II diabetes diagnosis), obese waist circumference (≥102 cm)
(1)   Index of Central Obesity for men = waist circumference cutoff / average national height > 0.58 
** Correlation is significant at the 0.01 level (2-tailed)
* Correlation is significant at the 0.05 level (2-tailed)
 
White                             
(n = 722)
Black                        
(n = 362)
Hispanic                     
(n = 225)
.180** .115* .015
.196** .123** .059
.352** .138** .246**
.213** .169**  .140*
Significance of association was measured using a two-tailed, partial correlation while controlling for age.
(2) Metabolic Syndrome Components for women: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking 
meds), raised triglycerides (≥150mg/dl), reduced HDL (<50 mg/dl), raised fasting blood glucose (≥100 mg/dl or 
Type II diabetes diagnosis), obese waist circumference (≥88 cm)
(1)   Index of Central Obesity for women = waist circumference cutoff / average national height > 0.54 
** Correlation is significant at the 0.01 level (2-tailed)
* Correlation is significant at the 0.05 level (2-tailed)
Table 10.  Correlation with ICO
1
 and Metabolic Syndrome Components
2
,                                                                                    
Age-Adjusted, Obese Female Study Population, NHANES 2005-2006
Raised Blood Pressure
2
Raised Triglycerides
2
Reduced HDL
2
Metabolic Syndrome 
Components
Raised Fasting Blood Glucose
2
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 Further evaluation of ICO’s relationship with the four metabolic syndrome 
components was conducted to determine if age influenced the correlation. The results of 
the correlation analyses, stratified by racial/ethnic groups and age groups (20-39, 40-59, 
60+), are reported in Table 11 (males) and Table 12 (females).  As shown, the majority of 
associations between ICO and metabolic syndrome was positive and significantly 
correlated (p <0.05), and most prevalent in obese white subjects and least frequent in 
obese Hispanics across race/ethnic and age groups.    
Among whites, blacks, and Hispanics, the degree of correlation between ICO and 
each metabolic syndrome component varied with respect to age.  No discernable patterns 
of association with increasing age were apparent across the racial/ethnic groups with 
respect to statistical significance or strength of correlation. Overall, no specific trend was 
observed between ICO and metabolic syndrome components with respect to advancing 
age. 
White                             
(n = 314)
Black                        
(n = 164)
Hispanic                     
(n = 91)
White                             
(n = 340)
Black                        
(n = 148)
Hispanic                  
(n = 70)
White                             
(n = 424)
Black                        
(n = 148)
Hispanic                  
(n = 78)
.212** .220** .164 .242** .146 -.057 .151** .291** .051
.078 .195* .194 .231** .043 .033 .082 .203* .029
.293** .121 .313** .232** .299** .051 .230** .126 .374**
.226** .073 .178 .161** .097 .332** .133** .203* .328**
Signficance of bivariate correlation was measured using Spearmans Rho.
Metabolic Syndrome 
Components
Table 11.  Age-Specific Correlation with ICO
1
 and Metabolic Syndrome Components
2
,                                                                                              
Obese Male Study Population, NHANES 2005-2006
Age 40 - 59 Age 60+Age 20 - 39
Raised Blood Pressure
2
Raised Triglycerides
2
Reduced HDL
2
(2) Metabolic Syndrome Components for men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides (≥150mg/dl), reduced HDL (<40 
mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis), obese waist circumference (≥102 cm)
(1) Index of Central Obesity for men = waist circumference cutoff / average national height > 0.58 
** Correlation is significant at the 0.01 level (2-tailed)
* Correlation is significant at the 0.05 level (2-tailed)
Raised Fasting Blood Glucose
2
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White                             
(n = 408)
Black                        
(n = 195)
Hispanic                    
(n = 136)
White                             
(n = 332)
Black                        
(n = 180)
Hispanic                   
(n = 88)
White                             
(n = 380)
Black                        
(n = 128)
Hispanic                  
(n = 72)
.078 .122 -.045 .274** .231** .124 .147** -.040 .000
.148** .165* .045 .210** .087 .007 .219** .071 .249*
.430** .175* .259** .324** .211* .325** .282** -.020 .130
.132** .194** .198* .323** .131 .155 .194** .200* -.006
Signficance of bivariate correlation was measured using Spearmans Rho.
Table 12.  Age-Specific Correlation with ICO
1
 and Metabolic Syndrome Components
2
,                                                                     
Obese Female Study Population, NHANES 2005-2006
Metabolic Syndrome 
Components
Raised Triglycerides
2
Reduced HDL
2
(1) Index of Central Obesity for women = waist circumference cutoff / average national height > 0.54 
** Correlation is significant at the 0.01 level (2-tailed)
* Correlation is significant at the 0.05 level (2-tailed)
Raised Blood Pressure
2
Raised Fasting Blood Glucose
2
Age 20 - 39 Age 40 - 59 Age 60+
 
 
4.3 Univariate Analysis Between Central Obesity Indicators & Metabolic Syndrome 
Components 
 
 Binary logistic regression was performed to quantify the association of ICO and 
WC obesity with metabolic syndrome components.  Stratified by race/ethnicity, the odds 
of centrally obesity and raised blood pressure, raised fasting glucose, raised triglycerides, 
or reduced HDL are shown in Table 13 and Table 14 for males and females respectively.  
Both WC and ICO were associated with increased odds of each metabolic syndrome 
component.  The odds ratios were not statistically significant in Hispanic females’ ICO 
status and high blood pressure or between Hispanic males’ WC and high blood pressure 
and raised blood glucose.  All other odds ratios were statistically significant.  
In Table 13 and Table 14, the odds ratios varied between central obesity indices 
with metabolic syndrome components.  In males, the majority of metabolic syndrome 
components had a stronger association with ICO compared to WC, but not statistically 
significant.  A much stronger associations were observed in Hispanic males with all four 
metabolic syndrome components, black males with hypertension or reduced HDL, and 
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white males with hypertension compared to a WC >102cm.  As for the females, both WC 
and ICO had similar association with the metabolic syndrome components.  
Although not statistically different, white subjects had the highest odds with the 
majority of metabolic syndrome components. ICO parameters were associated with 
highest odds for raised blood pressure and raised fasting blood glucose in the white males 
while Hispanic males had the highest odds for raised triglycerides and reduced HDL.  
White males with WC >102cm were the most likely to have raised blood pressure, raised 
fasting blood glucose, and raised triglycerides among the races/ethnicities.  White 
females with an ICO >0.54 or a WC >88cm had the highest odds of having any of the 
four metabolic syndrome components compared to blacks and Hispanics. 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Whites       
(n = 524)
3.2 (2.5 - 4.0) 2.4 (1.8 - 3.1) 2.6 (2.0 - 3.4) 2.0 (1.5 - 2.6)
Blacks       
(n = 187) 
2.8 (1.9 - 4.2) 2.2 (1.4 - 3.2) 2.4 (1.5 - 3.8) 2.0 (1.1 - 3.5)
Hispanics    
(n = 118)
1.8 (1.0 - 3.1) 1.7 (1.0 - 2.9) 2.9 (1.7 - 5.0) 3.2 (1.8 - 5.9)
Total           
(n = 829)
2.7 (2.2 - 3.3) 2.2 (1.8 - 2.7) 2.6 (2.2 - 3.2) 2.2 (1.7 - 2.8)
Whites       
(n = 538)
2.8 (2.2 - 3.5) 2.5 (1.9 - 3.2) 2.6 (2.0 - 3.3) 2.3 (1.7 - 3.0)
Blacks       
(n = 199) 
2.5 (1.7 - 3.6) 2.2 (1.5 - 3.4) 2.4 (1.5 - 3.8) 1.9 (1.0 - 3.3)
Hispanics    
(n = 101)
1.4 (0.8 - 2.4) 1.5 (0.9 - 2.6) 2.5 (1.5 - 4.4) 2.3 (1.3 - 4.1)
Total           
(n = 838)
2.4 (2.0 - 2.9) 2.2 (1.8 - 2.7) 2.5 (2.0 - 3.0) 2.2 (1.7 - 2.8)
OR and 95% CI were calculated using binary logistic regression;  (1) ICO for men = waist circumference cutoff / average national height > 0.58;  (2) Obese WC 
for men > 102cm;  (3) Metabolic Syndrome Components for men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides 
(≥150mg/dl), reduced HDL (<40 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis)
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Table 13.  Univariate Association of ICO
1
 and WC
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 with Metabolic Syndrome Components
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,                                                                                              
Male Study Population by Race, NHANES 2005-2006
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OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Whites       
(n = 722)
3.1 (2.3 - 4.1) 4.7 (3.1 - 7.1) 5.9 (4.3 - 8.1) 3.2 (2.3 - 4.5)
Blacks       
(n = 362) 
2.6 (1.7 - 4.0) 2.4 (1.4 - 4.0) 3.2 (1.6 - 6.4) 2.7 (1.5 - 4.8)
Hispanics    
(n = 225)
1.7 (0.9 - 3.4) 2.1 (1.1 - 4.0) 4.3 (2.2 - 8.5) 2.3 (1.2 - 4.3)
Total          
(n = 1309)
2.7 (2.2 - 3.4) 3.4 (2.6 - 4.6) 4.6 (3.6 - 6.0) 2.9 (2.3 - 3.9)
Whites       
(n = 711)
2.9 (2.2 - 3.9) 4.9 (3.2 - 7.5) 5.7 (4.2 - 7.8) 3.0 (2.2 - 4.3)
Blacks       
(n = 368) 
2.7 (1.8 - 4.2) 2.2 (1.3 - 3.7) 2.1 (1.1 - 4.0) 3.0 (1.6 - 5.6)
Hispanics    
(n = 206)
1.6 (0.9 - 2.9) 2.3 (1.2 - 4.2) 4.9 (2.6 - 9.1) 2.9 (1.6 - 5.4)
Total            
(n = 1285)
2.7 (2.2 - 3.3) 3.4 (2.6 - 4.6) 4.3 (3.3 - 5.5) 3.0 (2.3 - 3.9)
OR and 95% CI were calculated using binary logistic regression;  (1) ICO for women = waist circumference cutoff / average national height > 0.54;  (2) Obese 
WC for women > 88cm;  (3) Metabolic Syndrome Components for women: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised 
triglycerides (≥150mg/dl), reduced HDL (<50 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis) 
Metabolic Syndrome Components
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Table 14.  Univariate Association of ICO
1
 and WC
2
 with Metabolic Syndrome Components
3
,                                                                                              
Female Study Population by Race, NHANES 2005-2006
Raised                         
Blood Pressure
Raised                        
Fasting Blood Glucose
Raised                     
Triglycerides
Reduced                           
HDL
 
Additional analysis was conducted to determine if trends in age influenced the 
association of central obesity with metabolic syndrome components.  Stratified by the 
three age groups (20-39, 40-59, 60+),  binary logistic regression calculated the odds of 
being ICO or WC obese with raised blood pressure, raised fasting glucose, raised 
triglycerides, or reduced HDL, which are shown in Table 15 (males) and Table 16 
(females).  All odds ratios were statistically different between obese and non-obese 
subjects across all age groups. 
The strength of association with central obesity and metabolic syndrome 
components differed across age and gender.  The association tended to be higher in the 
youngest subjects, 20-39 years of age, in both WC and ICO categories.  In males, ICO 
demonstrated higher odds in the majority of metabolic syndrome components, which may 
indicate a better parameter for metabolic syndrome in males.   However, in the female 
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analysis, the WC appeared to be a stronger risk factor for metabolic syndrome 
components than ICO in the majority of strata.   
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Age 20 - 39      
(n = 178)
2.7 1.8 - 4.1 2.2 1.4 - 3.6 2.8 1.9 - 4.1 2.3 1.5 - 3.4
Age 40 - 59       
(n = 266) 
2.0 1.4 - 2.8 1.9 1.3 - 2.7 2.6 1.8 - 3.6 2.4 1.6 - 3.7
Age 60+    
(n = 385)
2.0 1.4 - 2.7 1.5 1.1 - 2.1 2.8 2.0 - 3.9 2.9 1.8 - 4.6
Total           
(n = 829)
2.7 (2.2 - 3.3) 2.2 (1.8 - 2.7) 2.6 (2.2 - 3.2) 2.2 (1.7 - 2.8)
Age 20 - 39      
(n = 189)
2.4 1.6 - 3.7 2.3 1.4 - 3.7 2.8 1.9 - 4.1 2.5 1.7 - 3.8
Age 40 - 59       
(n = 274) 
2.0 1.4 - 2.8 1.7 1.2 - 2.5 2.4 1.7 - 3.3 2.4 1.6 - 3.7
Age 60+    
(n = 375)
1.7 1.2 - 2.4 1.7 1.3 - 2.4 2.4 1.7 - 3.3 2.4 1.5 - 3.7
Total           
(n = 838)
2.4 (2.0 - 2.9) 2.2 (1.8 - 2.7) 2.5 (2.0 - 3.0) 2.2 (1.7 - 2.8)
OR and 95% CI were calculated using binary logistic regression;  (1) ICO for men = waist circumference cutoff / average national height > 0.58;  (2) Obese WC 
for men > 102cm;  (3) Metabolic Syndrome Components for men: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides 
(≥150mg/dl), reduced HDL (<40 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis) 
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Table 15.  Univariate Association of ICO
1
 and WC
2
 with Metabolic Syndrome Components
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Male Study Population by Age Group, NHANES 2005-2006
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OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Age 20 - 39      
(n = 448)
2.2 1.0 - 4.7 4.0 1.8 - 8.5 5.7 3.7 - 8.7 2.3 1.6 - 3.4
Age 40 - 59       
(n = 407) 
3.1 2.1 - 4.5 2.4 1.5 - 3.8 4.7 2.9 - 7.6 4.1 2.6 - 6.6
Age 60+    
(n = 454)
1.7 1.1 - 2.7 3.1 1.9 - 5.0 3.0 1.9 - 4.8 3.6 1.8 - 6.9
Total          
(n = 1309)
2.7 (2.2 - 3.4) 3.4 (2.6 - 4.6) 4.6 (3.6 - 6.0) 2.9 (2.3 - 3.9)
Age 20 - 39      
(n = 448)
2.2 1.0 - 4.7 5.6 2.3 - 13.2 6.5 4.2 - 10.1 2.3 1.5 - 3.4
Age 40 - 59       
(n = 409) 
4.2 2.8 - 6.2 2.5 1.6 - 4.0 4.1 2.6 - 6.5 3.8 2.4 - 6.1
Age 60+    
(n = 428)
1.9 1.3 - 2.9 3.2 2.0 - 5.0 2.5 1.7 - 3.8 3.9 2.1 - 7.1
Total            
(n = 1285)
2.7 (2.2 - 3.3) 3.4 (2.6 - 4.6) 4.3 (3.3 - 5.5) 3.0 (2.3 - 3.9)
OR and 95% CI were calculated using binary logistic regression;  (1) ICO for women = waist circumference cutoff / average national height > 0.54;  (2) Obese WC 
for women > 88cm;  (3) Metabolic Syndrome Components for women: raised blood pressure (≥135 systolic, ≥85 diastolic, or taking meds), raised triglycerides 
(≥150mg/dl), reduced HDL (<50 mg/dl), raised fasting blood glucose (≥100 mg/dl or Type II diabetes diagnosis)
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Table 16.  Univariate Association of ICO
1
 and WC
2
 with Metabolic Syndrome Components
3
,                                                                                              
Female Study Population by Age Group, NHANES 2005-2006
Raised                         
Blood Pressure
Raised                        
Fasting Blood Glucose
Raised                     
Triglycerides
Reduced                           
HDL
Metabolic Syndrome Components
 
4.4 Multivariate Analysis Between Central Obesity Indicators &  Metabolic 
Syndrome Components 
 
 To obtain a more accurate estimate of the true association of central obesity with 
metabolic syndrome components, multivariate regression was conducted.   These 
analyses took into account several predictive variables simultaneously which controlled 
for age, education level, income level, health insurance status, smoking history, alcohol 
use, physical activity, and family history.  The likelihood of being ICO or WC obese with 
each metabolic syndrome component was stratified by white, black, and Hispanic 
subjects and reported in Table 17, Table 18, and Table 19 respectively. 
 Shown in all three tables, most of the independent variables were not statistically 
significant among the races/ethnicities in both genders.  Regarding race/ethnicity, the 
obese white subjects had elevated risks for each metabolic syndrome component 
(p<0.05), the obese black subjects had elevated risks for each metabolic syndrome 
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component but not consistently significant, and the obese Hispanic subjects had elevated 
and reduced risks for metabolic syndrome components but not statistically significant in 
all cases.  With respect to gender, females with a WC >88cm tended to have higher odds 
with metabolic syndrome components than females with an ICO >0.54, with exception to 
the blacks’ glucose and triglyceride levels.  Males with an ICO >0.58 consistently had 
higher odds of having raised blood pressure compared to males with a WC >102cm.  
However, the odds of raised blood glucose, raised triglycerides, and reduced HDL varied 
between ICO and WC among the white, black, and Hispanic obese males.  Overall, 
central obesity based on WC classification was associated with higher odds in twice as 
many strata compared to ICO. 
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CHAPTER V 
DISCUSSION AND CONCLUSION 
5.1 Discussion 
Based on our results, we failed to reject the null hypothesis and were unable to 
support ICO as a better parameter for metabolic syndrome diagnosis compared to WC 
among white, black, and Hispanic adults in the United States.  Our findings included:  (1) 
subjects with ICO or obese WC had elevated risks of raised blood pressure, raised blood 
glucose, raised triglycerides, and reduced HDL, (2) the association between ICO and 
each metabolic syndrome component was not significantly different from WC, (3) the 
odds of having raised blood pressure, raised blood glucose, raised triglycerides, or 
reduced HDL was not consistently higher in either ICO or WC and varied between 
race/ethnicity and gender, (4) the correlation and association of central obesity and 
metabolic syndrome components was found statistically significant more often in white 
subjects compared to black and Hispanic subjects, and (5) prevalence of ICO increased as 
age increased, but age did not influence the correlation and association of ICO with 
metabolic syndrome components. 
 Differences of demographic factors, behavioral factors, and medical history were 
observed in the study subpopulations, with a focus centered on the racial/ethnic and 
gender disparities regarding anthropometric measurements and risk for metabolic 
syndrome components.  Prevalence of obesity among the racial/ethnic groups depended 
on the anthropometric parameter used.  Our analysis indicated 33% of men and 37 % of 
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women from our study population were considered obese with a BMI ≥30.   When 
stratified by race/ethnicity, disparities in the prevalence of obese BMI measurements 
were found in the females but not in the males.  Approximately 54% of black women and 
41% of Hispanic women were obese compared to 32% of white women.  These results 
were very similar to the 2003-2004 prevalence of obesity in the United States reported by 
the Centers for Disease Control and Prevention (CDC).66  However, when our study 
population was measured for central obesity by WC and WHtR parameters, the 
prevalence within the groups increased, but the gap between the groups decreased 
considerably among the black, Hispanic, and white females (73%, 70%, 64% and 72%, 
76%, 65% respectively).   While WC identified a larger proportion of centrally obese in 
white and black males and females, Hispanics had the highest prevalence of central 
obesity based on ICO. When stratified by ICO status, Hispanic subjects with an ICO were 
more likely to have coexisting normal WC measurements compared to whites and blacks.   
 Other notable racial/ethnic and gender differences were observed with respect to 
height measurements, waist circumference measurements, and clinical measurements.  
Comparing genders, women had higher rates of obesity based on all anthropometric 
measurements: BMI, WC, and ICO.  However, the females had lower rates of metabolic 
syndrome components (hypertension, elevated triglycerides, and elevated fasting blood 
glucose), with exception to the higher rates of reduced HDL levels in black and white 
obese females.  The lower rates may be contributable to the protective influence of 
gynoid adiposity on insulin resistance, which is common in the female phenotype.7, 12, 14, 
61  When stratified by ICO status, obese females and obese males had very similar WHtR 
averages ranging from 0.64 to 0.66.  This may indicated that a WHtR is a closer 
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agreement of parameters between genders and may adjust for sexual dimorphism.  
Having a single WHtR value to measure central obesity in either gender is a plausible 
concept. 
Comparing race/ethnicity, Hispanics tended to be shorter than whites and blacks, 
larger in girth than whites, and had higher rates of ICO than whites and blacks.  A larger 
proportion of Hispanics was affected by raised triglycerides, reduced HDL, and raised 
fasting blood glucose compared to whites and blacks, although glucose levels were not 
statistically different.  The ICO appears to be encompassing the adjustment for the 
smaller stature in the Hispanic population.  Further analysis of univariate and multivariate 
binary logistic regression indicated racial/ethnic inequalities with respect to the 
association of ICO and WC parameters with metabolic syndrome components.  During 
univariate analysis, white subjects (particularly males) with an ICO presented higher risks 
for metabolic syndrome components compared to WC.  When age, education, income, 
health insurance status, smoking status, alcohol use, physical activity, and family history 
were controlled for, ICO and WC remained a statistical significant indicator in the white 
subjects, but less significant in the black and Hispanics. These results may be a reflection 
of the ICO parameters derived from previous studies and national averages, which is 
heavily dominated by the white race. The United States adult population is comprised of 
approximately 76% Caucasians.67  Ethnic-specific ICO cut-points may be needed for the 
diverse groups in the United States. 
 
5.2 Limitations 
 
 This study does present some limitations.  Restrictions existed due to the study 
design and the nature of secondary data.  First, the cross-sectional design does not allow 
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for temporality and direction of risk factors and health outcomes.  From this design, it is 
indeterminable if central obesity occurred before or after metabolic syndrome 
components developed.  Second, the secondary data obtained from NHANES 2005-2006 
did not provide sufficient information to satisfy IDF’s definition of metabolic syndrome 
components.  For example, NHANES inquires “are you taking prescribed medication for 
high cholesterol” but does not prompt the subject for the type of cholesterol being 
treated.68  Cholesterol-reducing medications include the following categories: (1) statins 
lower LDL and modestly lower triglycerides and raise HDL, (2) selective cholesterol 
absorption inhibitors lower LDL and modestly lower triglycerides and raise HDL, (3) 
resins lower LDL, (4) fibrates lower triglycerides and sometime increase HDL, and (5) 
niacin lowers triglycerides and LDL and raises HDL.69  Since it is undetermined what 
cholesterols are being affected, subjects who reported they were taking cholesterol 
medication in conjunction with normal triglyceride and HDL levels were omitted as 
having elevated triglycerides or reduced HDL. This may have underestimated the 
prevalence of hyperlipidemia and distorted the correlation and association.  Case in point, 
the prevalence of male subjects with elevated triglyceride levels potentially could have 
increased from 39.4% to 47.2% if subjects taking cholesterol medication were included. 
And the third limitation in our study design hinders the application of our findings to the 
general public. These results can not be generalized to the entire United States population 
because our delimitations excluded subjects under the age 20 and races/ethnicities other 
than white, black, or Hispanic. 
Another limitation was in the definition of WC parameters.  IDF defines central 
obesity using gender and ethnic-specific WC cut-points.  They acknowledge that these 
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are pragmatic cut-points and that further research is required for risk assessment.  Even 
so, guidelines for IDF WC cut-points for the white, black, and Hispanic populations in 
the United States are unclear.  IDF recommends: (1) United States citizens of Europid 
origin should use both European [≥94cm for men, ≥80cm for women) and North 
American [≥102cm for men, ≥88cm for women] cut-points during epidemiological 
studies, but comments that NCEP ATP-III cut-points will be used in clinical settings, (2) 
Sub-Saharan Africans should use European data until more specific data are available, (3) 
Arab populations should use European data until more specific data are available, and (4) 
ethnic South and Central Americans should use South Asian recommendations [≥90cm 
for men, ≥80cm for women] until more specific data are available.  When referring to 
European data, it was uncertain if the black Americans of Sub-Saharan and Arab descent 
should use Europid cut-points or use North American cut-points. Also Hispanics were 
confined to ethnic South and Central Americans. Based on the ambiguity and the 
emphasis on current clinical practices in the United States, NCEP ATPIII WC cut-points 
were used for white, black, and Hispanic adults study population.  Ethnic-specific cut-
points for WC and ICO for this study population may have produced different results. 
 
5.3 Recommendations for Future Research 
 
First, future research should conduct longitudinal studies to determine which 
WHtR value is most effective for screening central obesity and predicting metabolic 
syndrome in white, black, and Hispanic adults of the United States. Previous studies 
conducted ROC analysis to determine the WHtR value most sensitive to metabolic 
syndrome components.  Researchers may want to design similar studies to determine if 
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other WHtR cut-points are better indicators of metabolic syndrome than the ICO 
parameters used in this study.  Second, researchers may want to analyze for spurious 
affects with respect to the correlation of WHtR with metabolic syndrome components, as 
suggested by Molarius and Seidall.70  They indicate that short stature has been associated 
with increased morbidity and may create a false correlation between WHtR and health 
events.  Studies should address this issue and test for validity.  And lastly, public health 
experts should evaluate the different parameters of central obesity and determine which is 
the most sensitive for detecting metabolic syndrome.  A single definition of metabolic 
syndrome needs to be created to best capture the risk of this disorder across all 
populations.   
 
5.4 Conclusion   
 Central obesity is a risk factor that can lead to insulin resistance and metabolic 
syndrome.  Those with metabolic syndrome have significantly higher risks for developing 
diabetes or CVD.  Public health experts estimate that billions of dollars in medical 
expenditures and indirect costs are spent managing patients with diabetes and CVD each 
year in the United States.  Morbidity and mortality stemming from central obesity has 
reached epidemic proportions.  Implementing a central obesity parameter that can 
accurately capture those at risk of developing metabolic syndrome is crucial.       
 Although this study failed to support the hypothesis that ICO was a better 
parameter for metabolic syndrome for the white, black, and Hispanic American adults, 
ICO should be considered a robust measurement for estimating central obesity and 
metabolic syndrome risk in addition to WC.  ICO was found to be highly correlated and 
exposed adults to elevated risks for hypertension, dyslipidemia, and insulin resistance. 
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Future studies may discover a more sensitive ICO cut-point value that identifies a larger 
portion of individuals at elevated risks for metabolic syndrome.  Nonetheless, a universal 
definition of metabolic syndrome is pertinent to improve screening and surveillance of 
central obesity across all populations.   
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